Skip to content

Johnson & Johnson JNJ MEDTECH — Goodwill, related to acquisitions

Other segment segments

Innovative Medicine
$0

Similar metrics at other companies

Stryker logo
SYKMedSurg and Neurotechnology: — Goodwill
$11.95B
Boston Scientific logo
BSXMedSurg — Goodwill acquired
$274M
Baxter International logo
BAXMedical Products & Therapies — Goodwill
$1.25B+2.0%
Baxter International logo
BAXHealthcare Systems & Technologies — Goodwill
$3.08B-13.4%
Henry Schein logo
HSICGlobal Technology — Goodwill Acquired
$6.5M
Boston Scientific logo
BSXMedSurg — Goodwill
$7.98B+6.4%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's medtech — goodwill, related to acquisitions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's MEDTECH — goodwill, related to acquisitions?
Johnson & Johnson (JNJ) reported MEDTECH — goodwill, related to acquisitions of $0 in Q1 2026.
What does MEDTECH — goodwill, related to acquisitions mean?
Captures the specific portion of goodwill added to the MedTech segment balance sheet resulting from new business combinations during the period. It quantifies the excess purchase price paid for medical device companies over their tangible net asset value.